ReviewCancer communications (London, England)2026
The Spatiotemporal Heterogeneity of Tumor-Associated Stromal Cells: Reprogramming Plasticity to Unlock Precision Cancer Immunotherapy.
Review in Cancer communications (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Spatial ecotype in tumor immune exclusion: from spatial architecture to therapeutic strategies.Molecular cancer · 2026Review
- Spatial Heterogeneity of Intratumoral Microbiota and Its Roles in Tumor-Microbiota Interactions and Therapeutic Implications.Pathogens (Basel, Switzerland) · 2026Review
- Single-cell transcriptomic analysis of cutaneous squamous cell carcinoma identifies an NR1H3-associated angiogenic macrophage state.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumor-associated stromal cells (TASCs) are key architects of the tumor microenvironment (TME), playing a vital role in tumor development, metastasis, and therapeutic response. Their spatiotemporal heterogeneity, characterized by dynamic phenotypic plasticity, diverse cellular subtypes, and distinct spatial distributions, offers profound insights into tumor behavior and paves the way for innovative therapy development. In particular, stromal-immune interactions reveal the powerful capacity of TASCs to shape the immune landscape, highlighting their potential as targets in immunotherapy. Despite growing evidence in functional diversity, precise mechanisms underlying the temporal evolution and spatial organization of TASCs remain elusive, impeding clinical translation. This review delved into the molecular signatures and functional states of TASCs, emphasizing their roles in tumor dynamics and therapeutic resistance. We also discussed innovative strategies targeting the plasticity of TASCs to reverse immune evasion and potentiate immune-mediated tumor eradication. Future studies should prioritize identifying spatially resolved and mechanically defined biomarkers with multi-omics and machine learning approaches, enabling a comprehensive understanding of TASCs to bridge the gap from bench to bedside.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.